WO2005120487A3 - Präparat zur prophylaxe und therapie von stresszuständen, von funktionellen und organischen störungen des nervensystems und des stoffwechsels - Google Patents

Präparat zur prophylaxe und therapie von stresszuständen, von funktionellen und organischen störungen des nervensystems und des stoffwechsels Download PDF

Info

Publication number
WO2005120487A3
WO2005120487A3 PCT/DE2005/001073 DE2005001073W WO2005120487A3 WO 2005120487 A3 WO2005120487 A3 WO 2005120487A3 DE 2005001073 W DE2005001073 W DE 2005001073W WO 2005120487 A3 WO2005120487 A3 WO 2005120487A3
Authority
WO
WIPO (PCT)
Prior art keywords
well
disorders
functional
nervous system
preparation
Prior art date
Application number
PCT/DE2005/001073
Other languages
English (en)
French (fr)
Other versions
WO2005120487A2 (de
Inventor
Egon Tech
Original Assignee
Egon Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE202004009180U external-priority patent/DE202004009180U1/de
Priority claimed from DE202004009689U external-priority patent/DE202004009689U1/de
Application filed by Egon Tech filed Critical Egon Tech
Priority to EP05761475A priority Critical patent/EP1781279A2/de
Priority to US11/629,246 priority patent/US20090017047A1/en
Publication of WO2005120487A2 publication Critical patent/WO2005120487A2/de
Publication of WO2005120487A3 publication Critical patent/WO2005120487A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

Präparat zur Prophylaxe und Therapie von Stresszuständen, von funktionellen und organischen Störungen des Nervensystems und des Stoffwechsels, für die Anwendung bei Sonnenallergikern, gegen Sonnenbrand, als Regenerativ geschädigter Zellen/Zellsysteme und für das Wohlbefinden bei Mensch und Tier sowie Verfahren zur Isolierung von Zellbestandteilen aus Aloe barbadensis miller, zur Herstellung von energetisierten/magnetisierten Mikro- und Nanopartikeln und Verwendung von Zellbestandteilen. Bisherige Mittel zum Einsatz bei den oben genannten Indikationen sind kostenintensiv in der Herstellung oder haben nur ungenügende Wirkeigenschaften. Präparate, enthaltend Glycin, insbesondere in einer Gel-Formulierung, haben sich als einfach herzustellende Mittel und als überraschend vorteilhaft bei den verschiedensten Applikationen herausgestellt. Die Präparate eignen sich aufgrund der hervorragenden Eigenschaften von Glycin für die einfach umzusetzende äussere und/oder innere Anwendung und bieten damit eine effektive Prophylaxe und Behandlungsmöglichkeiten der unterschiedlichen betroffenen Körperbereiche bzw. der Verbesserung des gefühlten Zustands.
PCT/DE2005/001073 2004-06-11 2005-06-10 Präparat zur prophylaxe und therapie von stresszuständen, von funktionellen und organischen störungen des nervensystems und des stoffwechsels WO2005120487A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05761475A EP1781279A2 (de) 2004-06-11 2005-06-10 Präparat zur prophylaxe und therapie von stresszuständen, von funktionellen und organischen störungen des nervensystems und des stoffwechsels
US11/629,246 US20090017047A1 (en) 2004-06-11 2005-06-10 Preparation for the Prevention and Treatment of Stress Conditions as Well as Functional and Organic Disorders of the Nervous System and Metabolic Disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE202004009180.1 2004-06-11
DE202004009180U DE202004009180U1 (de) 2004-06-11 2004-06-11 Rezeptur für die äußere Anwendung bei Sonnenallergikern und gegen Sonnenbrand sowie für die äußere und innere Anwendung zur Streßminderung und Steigerung des Wohlbefindens bei Tier und Mensch
DE202004009689U DE202004009689U1 (de) 2004-06-18 2004-06-18 Präparat zur Prophylaxe und Therapie von Stresszuständen sowie von funktionellen und organischen Störungen des Nervensystems und des Stoffwechsels
DE202004009689.7 2004-06-18

Publications (2)

Publication Number Publication Date
WO2005120487A2 WO2005120487A2 (de) 2005-12-22
WO2005120487A3 true WO2005120487A3 (de) 2006-07-20

Family

ID=35094203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2005/001073 WO2005120487A2 (de) 2004-06-11 2005-06-10 Präparat zur prophylaxe und therapie von stresszuständen, von funktionellen und organischen störungen des nervensystems und des stoffwechsels

Country Status (3)

Country Link
US (1) US20090017047A1 (de)
EP (1) EP1781279A2 (de)
WO (1) WO2005120487A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3698780A1 (de) * 2004-08-09 2020-08-26 Enrique Melendez Hevia Glycin als nahrungergänzungsmittel zur vorbeugung und/oder behandlung einer durch einen virus in einem der kollagen bedürfenden menschen collagensynthese bedarf verursachten infektionskrankheit
DE102006051941A1 (de) 2006-01-24 2007-07-26 Egon Tech Multifunktionales Wirkstoffgemisch
DE202007007542U1 (de) * 2007-05-26 2007-10-04 Tech, Egon Aminosäure-Mineral-Peptid-Komplex, insbesondere quantenmechanisch modifiziert, als Arzneimittel zur Behandlung von Demenzerkrankungen
DE202010010638U1 (de) 2010-06-28 2010-10-21 Tech, Egon Nano-Hydrogele für die therapeutische und nichttherapeutische Behandlung, insbesondere zur Therapie von Stresszuständen und Regeneration
JP2023502966A (ja) * 2019-11-18 2023-01-26 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 脳の健康に使用するためのグルタチオンの増強のための組成物及び方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540582A (en) * 1983-04-29 1985-09-10 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
US4767751A (en) * 1984-01-25 1988-08-30 Beecham Group P.L.C. Topical drug release system
US5051258A (en) * 1989-10-13 1991-09-24 Natrol, Inc. Dietary supplement for children
WO1997020552A1 (en) * 1995-12-07 1997-06-12 Albert Einstein College Of Medicine Of Yeshiva University Treatment of negative and cognitive symptoms of schizophrenia with glycine and its precursors
US6048543A (en) * 1995-06-14 2000-04-11 Novartis Nutrition Ag Amino acid compositions and use thereof in clinical nutrition
US20030060486A1 (en) * 2001-02-15 2003-03-27 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
WO2004026295A2 (de) * 2002-09-17 2004-04-01 Phenion Gmbh & Co. Kg Verwendung von substanzen zum schutz der haut

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
DE10113334A1 (de) * 2001-03-20 2002-09-26 Cognis Deutschland Gmbh Quartäre Tenside
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540582A (en) * 1983-04-29 1985-09-10 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
US4767751A (en) * 1984-01-25 1988-08-30 Beecham Group P.L.C. Topical drug release system
US5051258A (en) * 1989-10-13 1991-09-24 Natrol, Inc. Dietary supplement for children
US6048543A (en) * 1995-06-14 2000-04-11 Novartis Nutrition Ag Amino acid compositions and use thereof in clinical nutrition
WO1997020552A1 (en) * 1995-12-07 1997-06-12 Albert Einstein College Of Medicine Of Yeshiva University Treatment of negative and cognitive symptoms of schizophrenia with glycine and its precursors
US20030060486A1 (en) * 2001-02-15 2003-03-27 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
WO2004026295A2 (de) * 2002-09-17 2004-04-01 Phenion Gmbh & Co. Kg Verwendung von substanzen zum schutz der haut

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D'SOUZA D C ET AL: "GLYCINE SITE AGONISTS OF THE NMDA RECEPTOR: A REVIEW", CNS DRUG REVIEWS, BRANFORD, CT, US, vol. 1, no. 2, 1995, pages 227 - 260, XP002935039, ISSN: 1080-563X *
HERESCO-LEVY U ET AL: "Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia", BRITISH JOURNAL OF PSYCHIATRY 1996 UNITED KINGDOM, vol. 169, no. NOV., 1996, pages 610 - 617, XP009056005, ISSN: 0007-1250 *
JOHNSON J W ET AL: "GLYCINE POTENTIATES THE NMDA RESPONSE IN CULTURED MOUSE BRAIN NEURONS", NATURE (LONDON), vol. 325, no. 6104, 1987, pages 529 - 531, XP002350824, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
EP1781279A2 (de) 2007-05-09
WO2005120487A2 (de) 2005-12-22
US20090017047A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
WO2003099195A3 (en) Immunomodulatory compounds and methods of use thereof
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
EP2468266A3 (de) Pharmazeutische Zusammensetzungen zur akuten Glucocorticoidtherapie
WO2003025149A3 (en) Cell populations which co-express cd49c and cd90
EP1411978A4 (de) Botulinustoxin bei der behandlung und prävention von akne
WO2002069963A3 (en) Compositions comprising ferulic acid, caffeic acid, tannic acid or ellagic acid and their use for the preparation of a medicament for the treatment of dermatological disorders
WO2004037184A3 (en) Methods for the treatment of skin disorders
WO2005123116A3 (en) Compositions and methods for treating or preventing oxalate-related disease
WO2005120487A3 (de) Präparat zur prophylaxe und therapie von stresszuständen, von funktionellen und organischen störungen des nervensystems und des stoffwechsels
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
EP3813859A1 (de) Lactobacillus plantarum zur hautpflege
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
WO2006105359A3 (en) Methods for stimulating hair growth by administering bmps
WO2008140820A3 (en) Aloe preparation for skin enhancement
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
CN110833581A (zh) 抗敏组合物、其制备方法、抗敏化妆品及其制备方法
WO2006041800A3 (en) 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated kv1.3 potassium channel
CN102210641A (zh) 负离子美容保健面膜及其制造方法
WO2009150408A3 (en) Topical antimuscarinic formulations
WO2006124375A3 (en) Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders
CN109350564A (zh) 一种复活草修复原液及其制备方法
ITRM20060237A1 (it) Uso dei probiotici nella prevenzione e nel trattamento delle congiuntiviti allergiche
WO2004071397A3 (en) Combination therapy of zd6474 with 5-fu or/and cpt-11
WO2005092303A3 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005761475

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1120050019438

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005761475

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11629246

Country of ref document: US